Sara Alsterlind Hurvitz

Title(s)Professor, Medicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. Hematol Oncol Clin North Am. 2023 Feb; 37(1):103-115. McAndrew NP, Hurvitz SA. PMID: 36435604.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine?+?pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE). Breast Cancer Res. 2023 Jan 11; 25(1):2. de Haas SL, Slamon DJ, Martin M, Press MF, Lewis GD, Lambertini C, Prat A, Lopez-Valverde V, Boulet T, Hurvitz SA. PMID: 36631725; PMCID: PMC9832665.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer. Breast. 2022 Dec 14; 67:94-101. Chan A, Ruiz-Borrego M, Marx G, Chien AJ, Rugo HS, Brufsky A, Thirlwell M, Trudeau M, Bose R, Garc?a-S?enz JA, Egle D, Pistilli B, Wassermann J, Cheong KA, Schnappauf B, Semsek D, Singer CF, Foruzan N, DiPrimeo D, McCulloch L, Hurvitz SA, Barcenas CH. PMID: 36702070.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 01 14; 401(10371):105-117. Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cort?s J. PMID: 36495879.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    5. Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discov. 2022 12 02; 12(12):2754-2762. Jerusalem G, Park YH, Yamashita T, Hurvitz SA, Modi S, Andre F, Krop IE, Gonz?lez Farr? X, You B, Saura C, Kim SB, Osborne CR, Murthy RK, Gianni L, Takano T, Liu Y, Cathcart J, Lee C, Perrin C. PMID: 36255231; PMCID: PMC9716244.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    6. Recent progress in antibody-drug conjugate therapy for cancer. Nat Cancer. 2022 12; 3(12):1412-1413. Hurvitz SA. PMID: 36539503.
      View in: PubMed   Mentions: Translation:Humans
    7. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. JAMA Oncol. 2022 Dec 01. Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. PMID: 36454580; PMCID: PMC9716438.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. Future Oncol. 2022 Oct; 18(32):3563-3572. Hurvitz SA, Bachelot T, Bianchini G, Harbeck N, Loi S, Park YH, Prat A, Gilham L, Boulet T, Gochitashvili N, Monturus E, Lambertini C, Nyawira B, Knott A, Restuccia E, Schmid P. PMID: 36382554.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. Eur J Cancer. 2023 Jan; 178:23-33. Loibl S, Loirat D, Tolaney SM, Punie K, Oliveira M, Rugo HS, Bardia A, Hurvitz SA, Brufsky AM, Kalinsky K, Cort?s J, O'Shaughnessy JA, Dieras V, Carey LA, Gianni L, Gharaibeh M, Preger L, Phan S, Chang L, Shi L, Piccart MJ. PMID: 36379186.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis. Cancers (Basel). 2022 Oct 15; 14(20). Swain SM, Macharia H, Cortes J, Dang C, Gianni L, Hurvitz SA, Jackisch C, Schneeweiss A, Slamon D, Valagussa P, du Toit Y, Heinzmann D, Knott A, Song C, Cortazar P. PMID: 36291835; PMCID: PMC9599862.
      View in: PubMed   Mentions: 1  
    11. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2022 Aug 29; 8(1):98. Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, O'Shaughnessy J, Cort?s J, Di?ras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K. PMID: 36038616; PMCID: PMC9424318.
      View in: PubMed   Mentions:
    12. Acute health-related quality of life outcomes and systemic inflammatory markers following contemporary breast cancer surgery. NPJ Breast Cancer. 2022 Aug 08; 8(1):91. Radin AS, Bower JE, Irwin MR, Asher A, Hurvitz SA, Cole SW, Crespi CM, Ganz PA. PMID: 35941136; PMCID: PMC9359976.
      View in: PubMed   Mentions:
    13. DESTINY-Changing Results for Advanced Breast Cancer. N Engl J Med. 2022 07 07; 387(1):75-76. Hurvitz SA. PMID: 35793210.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    14. Acute and Chronic Effects of Adjuvant Therapy on Inflammatory Markers in Breast Cancer Patients. JNCI Cancer Spectr. 2022 07 01; 6(4). Bower JE, Ganz PA, Irwin MR, Cole SW, Carroll J, Kuhlman KR, Petersen L, Garet D, Asher A, Hurvitz SA, Crespi CM. PMID: 35900175; PMCID: PMC9420043.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. NPJ Breast Cancer. 2022 Jun 09; 8(1):72. Carey LA, Loirat D, Punie K, Bardia A, Di?ras V, Dalenc F, Diamond JR, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O'Shaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, Cort?s J. PMID: 35680967; PMCID: PMC9184615.
      View in: PubMed   Mentions: 4  
    16. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 06; 20(6):691-722. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R. PMID: 35714673.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    17. A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer. Cancer. 2022 06 01; 128 Suppl 11:2209-2223. Harbeck N, Burstein HJ, Hurvitz SA, Johnston S, Vidal GA. PMID: 35536015.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat. 2022 Sep; 195(2):127-139. O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cort?s J. PMID: 35545724; PMCID: PMC9374646.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    19. Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. Clin Cancer Res. 2022 05 02; 28(9):1854-1862. Peddi PF, Fasching PA, Liu D, Quinaux E, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Cunningham JM, Weinshilboum RM, Pienkowski T, Eiermann W, Mart?n M, Bee V, Wang X, Wang L, Yang E, Slamon DJ, Hurvitz SA. PMID: 35110416.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    20. Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis. Ther Adv Med Oncol. 2022; 14:17588359221085556. Ghafouri SN, Nayeri RW, McAndrew NP, Hurvitz SA. PMID: 35401793; PMCID: PMC8988670.
      View in: PubMed   Mentions:
    21. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer. Clin Cancer Res. 2022 04 01; 28(7):1383-1390. Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roch? HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA. PMID: 35091441; PMCID: PMC9365365.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    22. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022 03 24; 386(12):1143-1154. Cort?s J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA, DESTINY-Breast03 Trial Investigators. PMID: 35320644.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansCTClinical Trials
    23. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221083956. Bardia A, Cortes J, Hurvitz SA, Delaloge S, Iwata H, Shao ZM, Kanagavel D, Cohen P, Liu Q, Cartot-Cotton S, Pelekanou V, O'Shaughnessy J. PMID: 35309087; PMCID: PMC8928355.
      View in: PubMed   Mentions: 4  
    24. Oncotype DX Recurrence Score in premenopausal women. Ther Adv Med Oncol. 2022; 14:17588359221081077. Zhang S, Fitzsimmons KC, Hurvitz SA. PMID: 35295864; PMCID: PMC8918761.
      View in: PubMed   Mentions: 1  
    25. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2022 Mar 01; 28(5):851-859. Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, Harbeck N, Hurvitz S, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, O'Regan R, Gasch C, Solovieff N, Wang C, Wang Y, Chakravartty A, Ji Y, Tripathy D. PMID: 34965945; PMCID: PMC9377723.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    26. Correlation between work productivity loss and EORTC QLQ-C30 and -BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2- advanced breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221081203. Tripathy D, Curteis T, Hurvitz S, Yardley D, Franke F, Babu KG, Wheatley-Price P, Im YH, Pencheva R, Eddowes LA, Dionne PA, Chandiwana D, Pathak P, Lanoue B, Harbeck N. PMID: 35251320; PMCID: PMC8891884.
      View in: PubMed   Mentions: 2  
    27. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Ann Oncol. 2022 03; 33(3):234-238. Tarantino P, Burstein HJ, Lin NU, Krop IE, Winer EP, Schnitt SJ, Hamilton EP, Hurvitz SA, Rugo HS, Curigliano G, Tolaney SM. PMID: 34942341.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. JCO Oncol Pract. 2022 04; 18(4):e484-e494. D'Ambruoso SF, Glaspy JA, Hurvitz SA, Wenger NS, Pietras C, Ahmed K, Drakaki A, Goldman JW, Anand S, Simon W, Kung J, Coscarelli A, Rosen LS, Peddi PF, Wong DJL, Santos K, Phung P, Karlin D, Walling AM. PMID: 34748398.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2- Advanced Breast Cancer. Cancer Manag Res. 2021; 13:8179-8189. Fasching PA, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, Lanoue B, Hu H, Thuerigen A, O'Shaughnessy J. PMID: 34754238; PMCID: PMC8570288.
      View in: PubMed   Mentions:
    30. A careful reassessment of anthracycline use in curable breast cancer. NPJ Breast Cancer. 2021 Oct 08; 7(1):134. Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, Fasching PA, Ejlertsen B, Yang EH, Glaspy JA, Slamon DJ. PMID: 34625570; PMCID: PMC8501074.
      View in: PubMed   Mentions: 10  
    31. Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer. Breast Cancer Res Treat. 2021 Dec; 190(3):357-372. Van Belle H, Hurvitz SA, Gilbar PJ, Wildiers H. PMID: 34533681.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 Sep 01; 27(17):4939. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. PMID: 34470810.
      View in: PubMed   Mentions:    Fields:    
    33. A plain language summary of the ASCENT�study: Sacituzumab Govitecan for metastatic triple-negative breast cancer. Future Oncol. 2021 Oct 01; 17(30):3911-3924. Bardia A, Hurvitz SA, Rugo HS, Brufsky A, Cortes J, Loibl S, Piccart M, Cowden J, Spears P, Carey LA. PMID: 34467774.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    34. Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. JCO Precis Oncol. 2021; 5. Bardia A, Su F, Solovieff N, Im SA, Sohn J, Lee KS, Campos-Gomez S, Jung KH, Colleoni M, V?zquez RV, Franke F, Hurvitz S, Harbeck N, Chow L, Taran T, Rodriguez Lorenc K, Babbar N, Tripathy D, Lu YS. PMID: 34504990; PMCID: PMC8423397.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    35. Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer. Clin Cancer Res. 2021 11 01; 27(21):5818-5827. Saura C, Matito J, Oliveira M, Wildiers H, Brufksy AM, Waters SH, Hurvitz SA, Moy B, Kim SB, Gradishar WJ, Queiroz GS, Cronemberger E, Wallweber GJ, Bebchuk J, Keyvanjah K, Lalani AS, Bryce R, Vivancos A, Eli LD, Delaloge S. PMID: 34380637; PMCID: PMC9401509.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    36. Cycling cancer persister cells arise from lineages with distinct programs. Nature. 2021 08; 596(7873):576-582. Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, H?tter JC, Hu B, Thakore PI, Tabaka M, Fulco CP, Colgan W, Cuevas BM, Hurvitz SA, Slamon DJ, Deik A, Pierce KA, Clish C, Hata AN, Zaganjor E, Lahav G, Politi K, Brugge JS, Regev A. PMID: 34381210; PMCID: PMC9209846.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCells
    37. Sacituzumab Govitecan in Metastatic Breast Cancer. Reply. N Engl J Med. 2021 07 15; 385(3):e12. Bardia A, Hurvitz SA, Rugo HS. PMID: 34260848.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    38. Can Women With HER2-Positive Metastatic Breast Cancer Be Cured? Clin Breast Cancer. 2021 12; 21(6):526-531. Haji F, Hurvitz SA. PMID: 34334312.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    39. Anthracycline Use in ERBB2-Positive Breast Cancer: It Is Time to Re-TRAIN. JAMA Oncol. 2021 07 01; 7(7):975-977. Hurvitz SA. PMID: 34014297.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    40. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. Oncologist. 2021 08; 26(8):e1327-e1338. Hurvitz SA, Saura C, Oliveira M, Trudeau ME, Moy B, Delaloge S, Gradishar W, Kim SB, Haley B, Ryvo L, Dai MS, Milovanov V, Alarc?n J, Kalmadi S, Cronemberger E, Souza C, Landeiro L, Bose R, Bebchuk J, Kabbinavar F, Bryce R, Keyvanjah K, Brufsky AM. PMID: 34028126; PMCID: PMC8342591.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    41. Finding the Sweet Spot in the Management of Early HER2+ Breast Cancer. JCO Oncol Pract. 2021 06; 17(6):331-333. Hurvitz SA. PMID: 34111380.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    42. Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. PLoS One. 2021; 16(5):e0251163. Zoeller JJ, Press MF, Selfors LM, Dering J, Slamon DJ, Hurvitz SA, Brugge JS. PMID: 33951110; PMCID: PMC8099090.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    43. NCCN Guidelines� Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 05 01; 19(5):484-493. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Matro J, Mayer IA, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns JL, Kumar R. PMID: 34794122.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    44. Neratinib?+?capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and?=?2 prior HER2-directed regimens. Breast Cancer Res Treat. 2021 Jul; 188(2):449-458. Moy B, Oliveira M, Saura C, Gradishar W, Kim SB, Brufsky A, Hurvitz SA, Ryvo L, Fagnani D, Kalmadi S, Silverman P, Delaloge S, Alarcon J, Kwong A, Lee KS, Ang PCS, Ow SGW, Chu SC, Bryce R, Keyvanjah K, Bebchuk J, Zhang B, Oestreicher N, Bose R, Chan N. PMID: 33909203; PMCID: PMC8260518.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    45. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021 04 22; 384(16):1529-1541. Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cort?s J, O'Shaughnessy J, Di?ras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS, ASCENT Clinical Trial Investigators. PMID: 33882206.
      View in: PubMed   Mentions: 157     Fields:    Translation:HumansCTClinical Trials
    46. Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response. Nat Cancer. 2021 04; 2(4):400-413. McNamara KL, Caswell-Jin JL, Joshi R, Ma Z, Kotler E, Bean GR, Kriner M, Zhou Z, Hoang M, Beechem J, Zoeller J, Press MF, Slamon DJ, Hurvitz SA, Curtis C. PMID: 34966897; PMCID: PMC8713949.
      View in: PubMed   Mentions: 9  Translation:Humans
    47. Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review. Breast. 2021 Jun; 57:95-103. Kolberg HC, Jackisch C, Hurvitz SA, Winstone J, Barham H, Hanes V, Courmier D. PMID: 33799233; PMCID: PMC8044716.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    48. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2- Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1). Clin Cancer Res. 2021 08 01; 27(15):4177-4185. Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley DA, Karuturi M, Sanft T, Blau S, Hart L, Ma C, Rugo HS, Purkayastha D, Moulder S. PMID: 33722897; PMCID: PMC8487593.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    49. Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Res Treat. 2021 Jul; 188(1):179-190. Kaufman PA, Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Brufsky AM, Rugo HS, Cobleigh M, Swain SM, Tripathy D, Morris A, Antao V, Li H, Jahanzeb M. PMID: 33641083.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    50. Do all patients with cancer experience fatigue? A longitudinal study of fatigue trajectories in women with breast cancer. Cancer. 2021 04 15; 127(8):1334-1344. Bower JE, Ganz PA, Irwin MR, Cole SW, Garet D, Petersen L, Asher A, Hurvitz SA, Crespi CM. PMID: 33606273; PMCID: PMC8562726.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    51. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clin Cancer Res. 2021 09 01; 27(17):4870-4882. De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, Litchfield LM, Liu J, Donaldson J, Selenica P, Brown DN, Weigelt B, Reis-Filho JS, Park BH, Hurvitz SA, Slamon DJ, Rimawi MF, Jansen VM, Jeselsohn R, Osborne CK, Schiff R. PMID: 33536276; PMCID: PMC8628647.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    52. Innovations in targeted therapies for triple negative breast cancer. Curr Opin Obstet Gynecol. 2021 02 01; 33(1):34-47. McCann KE, Hurvitz SA. PMID: 33093337.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    53. Betrayal Trauma: Impact on Health Professionals. Adv Mind Body Med. 2021 Winter; 35(1):34-37. Bursch B, Hurvitz S, Parikh M. PMID: 33513584.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Phase II randomized trial of a non-steroidal mouth wash for prevention and treatment of stomatitis in women with hormone receptor positive breast cancer treated with everolimus. Ther Adv Med Oncol. 2020; 12:1758835920967259. Peddi PF, Tetef M, Coluzzi P, Arzoo KK, Hu EH, Berkowitz MJ, Chan D, Moore D, Adams B, Wang X, Hurvitz SA. PMID: 33299473; PMCID: PMC7711222.
      View in: PubMed   Mentions:
    55. Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nat Commun. 2020 11 17; 11(1):5824. Hurvitz SA, Caswell-Jin JL, McNamara KL, Zoeller JJ, Bean GR, Dichmann R, Perez A, Patel R, Zehngebot L, Allen H, Bosserman L, DiCarlo B, Kennedy A, Giuliano A, Calfa C, Molthrop D, Mani A, Chen HW, Dering J, Adams B, Kotler E, Press MF, Brugge JS, Curtis C, Slamon DJ. PMID: 33203854; PMCID: PMC7673127.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    56. HER2DX: a tool that might inform treatment choices for HER2-positive breast cancer. Lancet Oncol. 2020 11; 21(11):1392-1393. Hurvitz SA. PMID: 33152281.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    57. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer. Breast Cancer Res. 2020 08 14; 22(1):89. O'Brien NA, McDermott MSJ, Conklin D, Luo T, Ayala R, Salgar S, Chau K, DiTomaso E, Babbar N, Su F, Gaither A, Hurvitz SA, Linnartz R, Rose K, Hirawat S, Slamon DJ. PMID: 32795346; PMCID: PMC7427086.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansAnimalsCells
    58. Oncological care organisation during COVID-19 outbreak. ESMO Open. 2020 08; 5(4). Onesti CE, Rugo HS, Generali D, Peeters M, Zaman K, Wildiers H, Harbeck N, Martin M, Cristofanilli M, Cortes J, Tjan-Heijnen V, Hurvitz SA, Berchem G, Tagliamento M, Campone M, Bartsch R, De Placido S, Puglisi F, Rottey S, M?ller V, Ruhstaller T, Machiels JP, Conte P, Awada A, Jerusalem G. PMID: 32847836; PMCID: PMC7451457.
      View in: PubMed   Mentions: 20  Translation:HumansCellsPHPublic Health
    59. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With = 2 HER2-Directed Regimens: Phase III NALA Trial. J Clin Oncol. 2020 09 20; 38(27):3138-3149. Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A, NALA Investigators. PMID: 32678716; PMCID: PMC7499616.
      View in: PubMed   Mentions: 149     Fields:    Translation:HumansCTClinical Trials
    60. Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. J Immunother Cancer. 2020 07; 8(2). Huang CS, Yu AL, Tseng LM, Chow LWC, Hou MF, Hurvitz SA, Schwab RB, L Murray J, Chang HK, Chang HT, Chen SC, Kim SB, Hung JT, Ueng SH, Lee SH, Chen CC, Rugo HS. PMID: 32718986; PMCID: PMC7380846.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    61. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020 08 10; 38(23):2610-2619. Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. PMID: 32468955; PMCID: PMC7403000.
      View in: PubMed   Mentions: 137     Fields:    Translation:Humans
    62. Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. Breast Cancer Res Treat. 2020 Jun; 181(2):233-248. Drullinsky PR, Hurvitz SA. PMID: 32274666.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    63. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020 02 13; 382(7):610-621. Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I, DESTINY-Breast01 Investigators. PMID: 31825192; PMCID: PMC7458671.
      View in: PubMed   Mentions: 416     Fields:    Translation:HumansCTClinical Trials
    64. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 02 13; 382(7):597-609. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, M?ller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. PMID: 31825569.
      View in: PubMed   Mentions: 333     Fields:    Translation:Humans
    65. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers (Basel). 2019 Dec 10; 11(12). Schneeweiss A, Hess D, Joerger M, Varga A, Moulder S, Tsimberidou AM, Ma C, Hurvitz SA, Rentzsch C, Rudolph M, Thiele S, Boix O, Wilkinson G, Lagkadinou E, Ocker M. PMID: 31835495; PMCID: PMC6966663.
      View in: PubMed   Mentions: 8  
    66. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Target Oncol. 2019 12; 14(6):647-656. Kolberg HC, Colleoni M, Santi P, Demetriou GS, Segui-Palmer MA, Fujiwara Y, Hurvitz SA, Hanes V. PMID: 31620980; PMCID: PMC6875516.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    67. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clin Cancer Res. 2020 03 01; 26(5):1105-1113. Cobleigh M, Yardley DA, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Hurvitz SA, O'Shaughnessy J, Mason G, Antao V, Li H, Chu L, Jahanzeb M. PMID: 31772121.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    68. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist. 2020 03; 25(3):e439-e450. Hurvitz SA, Gon?alves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J. PMID: 32162822; PMCID: PMC7066700.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCellsCTClinical Trials
    69. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectr. 2020 Feb; 4(1):pkz085. Rugo HS, Ettl J, Hurvitz SA, Gon?alves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W. PMID: 32337496; PMCID: PMC7050154.
      View in: PubMed   Mentions: 12     Fields:    
    70. Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer. Clin Cancer Res. 2020 02 01; 26(3):566-580. Hurvitz SA, Martin M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana S, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ. PMID: 31615937; PMCID: PMC7498177.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    71. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020 02; 25(2):e214-e222. Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G, O'Shaughnessy J, Rugo HS, Swain SM, Yardley DA, Chu L, Li H, Antao V, Hurvitz SA. PMID: 32043771; PMCID: PMC7011632.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    72. Advances in Targeted Therapies for Triple-Negative Breast Cancer. Drugs. 2019 Jul; 79(11):1217-1230. McCann KE, Hurvitz SA, McAndrew N. PMID: 31254268.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    73. Clinical features of pseudocirrhosis in metastatic breast cancer. Breast Cancer Res Treat. 2019 Sep; 177(2):409-417. Oliai C, Douek ML, Rhoane C, Bhutada A, Ge PS, Runyon BA, Wang X, Hurvitz SA. PMID: 31175499; PMCID: PMC6664810.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    74. Is the duration of adjuvant trastuzumab debate still clinically relevant? Lancet. 2019 06 29; 393(10191):2565-2567. Hurvitz SA. PMID: 31178153.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    75. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 07 25; 381(4):307-316. Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D. PMID: 31166679.
      View in: PubMed   Mentions: 262     Fields:    Translation:HumansCTClinical Trials
    76. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019 09 01; 37(25):2206-2216. Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D. PMID: 31157583; PMCID: PMC6774816.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    77. Neratinib Plus Capecitabine Provides a Glimmer of Hope for a Daunting Disease. J Clin Oncol. 2019 05 01; 37(13):1044-1046. Hurvitz SA. PMID: 30875278; PMCID: PMC6494353.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. Dose intensification of chemotherapy for early breast cancer in the age of de-escalation. Lancet. 2019 Apr 06; 393(10179):1390-1392. Hurvitz SA. PMID: 30739744.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    79. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). Clin Cancer Res. 2019 05 15; 25(10):2975-2987. Mayer IA, Prat A, Egle D, Blau S, Fidalgo JAP, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz S, Estévez LG, van Dam PA, Kümmel S, Mundhenke C, Holmes F, Babbar N, Charbonnier L, Diaz-Padilla I, Vogl FD, Sellami D, Arteaga CL. PMID: 30723140; PMCID: PMC6522303.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCellsCTClinical Trials
    80. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clin Cancer Res. 2019 04 15; 25(8):2433-2441. Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M. PMID: 30593513.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    81. Testing a biobehavioral model of fatigue before adjuvant therapy in women with breast cancer. Cancer. 2019 02 15; 125(4):633-641. Bower JE, Asher A, Garet D, Petersen L, Ganz PA, Irwin MR, Cole SW, Hurvitz SA, Crespi CM. PMID: 30561795; PMCID: PMC6373488.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    82. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res. 2019 05 01; 25(9):2717-2724. Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balma?a J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME, ABRAZO Study Group. PMID: 30563931.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    83. Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). Ther Adv Med Oncol. 2018; 10:1758835918807339. Hurvitz S, Singh R, Adams B, Taguchi JA, Chan D, Dichmann RA, Castrellon A, Hu E, Berkowitz J, Mani A, DiCarlo B, Callahan R, Smalberg I, Wang X, Meglar I, Martinez D, Hobbs E, Slamon DJ. PMID: 30542377; PMCID: PMC6236634.
      View in: PubMed   Mentions: 18  
    84. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. Eur J Cancer. 2018 11; 104:160-168. Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E, Mina LA, Balma?a J, Fasching PA, Bhattacharyya H, Hannah AL, Robson ME, Wardley AM. PMID: 30359909.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    85. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial. JAMA Oncol. 2018 10 01; 4(10):1367-1374. Jerusalem G, de Boer RH, Hurvitz S, Yardley DA, Kovalenko E, Ejlertsen B, Blau S, ?zg?roglu M, Landherr L, Ewertz M, Taran T, Fan J, Noel-Baron F, Louveau AL, Burris H. PMID: 29862411; PMCID: PMC6233772.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    86. Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. J Clin Oncol. 2018 Sep 20; JCO2017748392. Bardia A, Parton M, K?mmel S, Est?vez LG, Huang CS, Cort?s J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, L?pez R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB. PMID: 30235087.
      View in: PubMed   Mentions: 24     Fields:    
    87. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. Eur J Cancer. 2018 11; 103:147-154. Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cort?s J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouha?r S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J. PMID: 30241001.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    88. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018 08 23; 379(8):753-763. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon?alves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roch? H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. PMID: 30110579.
      View in: PubMed   Mentions: 619     Fields:    Translation:HumansCTClinical Trials
    89. Advances in the use of PARP inhibitor therapy for breast cancer. Drugs Context. 2018; 7:212540. McCann KE, Hurvitz SA. PMID: 30116283; PMCID: PMC6089618.
      View in: PubMed   Mentions: 48  
    90. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors. Invest New Drugs. 2018 12; 36(6):1060-1071. Carducci M, Shaheen M, Markman B, Hurvitz S, Mahadevan D, Kotasek D, Goodman OB, Rasmussen E, Chow V, Juan G, Friberg GR, Gamelin E, Vogl FD, Desai J. PMID: 29980894; PMCID: PMC6639057.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    91. Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances. Clin Cancer Res. 2018 11 01; 24(21):5206-5218. Bardia A, Hurvitz S. PMID: 29884743.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    92. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 07; 19(7):904-915. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. PMID: 29804902.
      View in: PubMed   Mentions: 263     Fields:    Translation:HumansCTClinical Trials
    93. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer. Mol Cancer Ther. 2018 05; 17(5):897-907. O'Brien N, Conklin D, Beckmann R, Luo T, Chau K, Thomas J, Mc Nulty A, Marchal C, Kalous O, von Euw E, Hurvitz S, Mockbee C, Slamon DJ. PMID: 29483214.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    94. Focal Irradiation and Systemic TGF� Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 06 01; 24(11):2493-2504. Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, Ratikan JA, Felix C, Hwang L, Faull KF, Sayre JW, Hurvitz S, Glaspy JA, Comin-Anduix B, Demaria S, Schaue D, McBride WH. PMID: 29476019; PMCID: PMC5999326.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCTClinical Trials
    95. Harnessing the immune system in the battle against breast cancer. Drugs Context. 2018; 7:212520. Nakasone ES, Hurvitz SA, McCann KE. PMID: 29456568; PMCID: PMC5810622.
      View in: PubMed   Mentions: 14  
    96. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 01; 19(1):115-126. Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Beckmann MW, Afenjar K, Fresco R, Helms HJ, Xu J, Lin YG, Sparano J, Slamon D. PMID: 29175149.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansCTClinical Trials
    97. Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. Clin Breast Cancer. 2018 04; 18(2):e205-e218. Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA. PMID: 29050918.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    98. Effect and Efficiency of an Embedded Palliative Care Nurse Practitioner in an Oncology Clinic. J Oncol Pract. 2017 09; 13(9):e792-e799. Walling AM, D'Ambruoso SF, Malin JL, Hurvitz S, Zisser A, Coscarelli A, Clarke R, Hackbarth A, Pietras C, Watts F, Ferrell B, Skootsky S, Wenger NS. PMID: 28813191.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    99. Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. Breast Cancer Res Treat. 2017 Nov; 166(1):145-156. Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA. PMID: 28702891.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    100. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 07; 18(7):904-916. Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. PMID: 28576675; PMCID: PMC5549667.
      View in: PubMed   Mentions: 221     Fields:    Translation:HumansCellsCTClinical Trials
    101. Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1. Breast Cancer Res. 2017 04 11; 19(1):47. Toi M, Shao Z, Hurvitz S, Tseng LM, Zhang Q, Shen K, Liu D, Feng J, Xu B, Wang X, Lee KS, Ng TY, Ridolfi A, Noel-Baron F, Ringeisen F, Jiang Z. PMID: 28399902; PMCID: PMC5387380.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    102. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA. 2017 02 14; 317(6):606-614. Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, B?geman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T. PMID: 28196257; PMCID: PMC5639721.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    103. Optimal Management of Early and Advanced HER2 Breast Cancer. Am Soc Clin Oncol Educ Book. 2017; 37:76-92. Hurvitz SA, Gelmon KA, Tolaney SM. PMID: 28561711.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    104. A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity. Oncotarget. 2016 Nov 29; 7(48):78577-78590. Huang Y, Burns DJ, Rich BE, MacNeil IA, Dandapat A, Soltani SM, Myhre S, Sullivan BF, Furcht LT, Lange CA, Hurvitz SA, Laing LG. PMID: 27713176; PMCID: PMC5346661.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    105. Use of a Shared Mental Model by a Team Composed of Oncology, Palliative Care, and Supportive Care Clinicians to Facilitate Shared Decision Making in a Patient With Advanced Cancer. J Oncol Pract. 2016 11; 12(11):1039-1045. D'Ambruoso SF, Coscarelli A, Hurvitz S, Wenger N, Coniglio D, Donaldson D, Pietras C, Walling AM. PMID: 27577617; PMCID: PMC5455417.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    106. Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic. Ann Surg Oncol. 2016 12; 23(Suppl 5):634-641. Kishan AU, Gomez CL, Dawson NA, Dvorak R, Foster NM, Hoyt A, Hurvitz SA, Kusske A, Silver EL, Tseng C, McCloskey SA. PMID: 27619940.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    107. Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer. Clin Adv Hematol Oncol. 2016 Jul; 14(7):520-30. Zhang B, Hurvitz S. PMID: 27379947.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    108. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer. 2016 06 03; 16:352. Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I, Yardley DA. PMID: 27259714; PMCID: PMC4893300.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    109. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. J Clin Oncol. 2016 06 20; 34(18):2115-24. Andr? F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D. PMID: 27091708.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCellsCTClinical Trials
    110. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Rep. 2016 Feb 23; 14(7):1590-1601. Hong CS, Graham NA, Gu W, Espindola Camacho C, Mah V, Maresh EL, Alavi M, Bagryanova L, Krotee PAL, Gardner BK, Behbahan IS, Horvath S, Chia D, Mellinghoff IK, Hurvitz SA, Dubinett SM, Critchlow SE, Kurdistani SK, Goodglick L, Braas D, Graeber TG, Christofk HR. PMID: 26876179; PMCID: PMC4816454.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansAnimalsCells
    111. Triple-negative breast cancer: advancements in characterization and treatment approach. Curr Opin Obstet Gynecol. 2016 Feb; 28(1):59-69. Hurvitz S, Mead M. PMID: 26694831.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    112. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol. 2016 Mar; 17(3):357-366. Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M, LUX-Breast 1 study group. PMID: 26822398.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    113. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol. 2015 Dec; 16(16):1700-10. Cort?s J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espi? M, Kim SB, Schneeweiss A, Sohn JH, Nabholtz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H. PMID: 26596672.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    114. NatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancer. Syst Rev. 2015 Oct 01; 4:133. Korner EJ, Morris A, Allen IE, Hurvitz S, Beattie MS, Kalesan B. PMID: 26428301; PMCID: PMC4591587.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    115. Breast cancer: The debate over post-mastectomy radiotherapy should continue. Nat Rev Clin Oncol. 2015 Oct; 12(10):567-8. Oliai C, Hurvitz SA. PMID: 26323387.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    117. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015 Jul; 16(7):816-29. Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D. PMID: 26092818.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansCTClinical Trials
    118. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. Breast. 2015 Jun; 24(3):182-90. Di?ras V, Wildiers H, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gon?alves A, Romieu G, Limentani SA, Jerusalem G, Lakshmaiah KC, Roch? H, S?nchez-Rovira P, Pienkowski T, Segu? Palmer M?, Li A, Sun YN, Pickett CA, Slamon DJ. PMID: 25747197.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    119. In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response. Breast Cancer Res Treat. 2015 Feb; 149(3):669-80. Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, Slamon DJ. PMID: 25663547.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    120. Symptom burden and quality of life among women with HER2(+) metastatic breast cancer. Breast J. 2015 Mar-Apr; 21(2):208-10. Mayer M, Lang K, Hurvitz S, Lalla D, Federico V, Brammer M, Menzin J, Tripathy D. PMID: 25655357.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    121. Estrogen receptor (ER)a-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression. J Biol Chem. 2015 Feb 27; 290(9):5566-81. Drew BG, Hamidi H, Zhou Z, Villanueva CJ, Krum SA, Calkin AC, Parks BW, Ribas V, Kalajian NY, Phun J, Daraei P, Christofk HR, Hewitt SC, Korach KS, Tontonoz P, Lusis AJ, Slamon DJ, Hurvitz SA, Hevener AL. PMID: 25468909; PMCID: PMC4342471.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansAnimalsCells
    122. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med. 2014 Dec; 2(12):122. Wong DJ, Hurvitz SA. PMID: 25568875; PMCID: PMC4260046.
      View in: PubMed   Mentions: 24  
    123. Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. Pharmgenomics Pers Med. 2014; 7:329-38. Sadeghi S, Olevsky O, Hurvitz SA. PMID: 25378946; PMCID: PMC4207068.
      View in: PubMed   Mentions: 4  
    124. Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014 Sep; 6(5):202-9. Peddi PF, Hurvitz SA. PMID: 25342987; PMCID: PMC4206612.
      View in: PubMed   Mentions: 25  
    125. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist. 2014 Sep; 19(9):901-8. Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D. PMID: 25085897; PMCID: PMC4153460.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    126. Antibody-drug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci. 2014 Aug; 1321:41-54. Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah DK, Haddish-Berhane N, Kabbarah O. PMID: 25123209.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    127. Cardiotoxicity of targeted agents in oncology: a medical oncology perspective. Oncology (Williston Park). 2014 Jun; 28(6):490-2. Wong DJ, Hurvitz SA. PMID: 25134322.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    128. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res. 2014 Jul 01; 20(13):3507-20. O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ. PMID: 24879796.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    129. Afatinib in the treatment of breast cancer. Expert Opin Investig Drugs. 2014 Jul; 23(7):1039-47. Hurvitz SA, Shatsky R, Harbeck N. PMID: 24870559.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    130. Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. Breast Cancer Res. 2014 May 23; 16(3):R50. Perez EA, Hurvitz SA, Amler LC, Mundt KE, Ng V, Guardino E, Gianni L. PMID: 24887458; PMCID: PMC4229898.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    131. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus. 2014; 3:259. Hansen RN, Ramsey SD, Lalla D, Masaquel A, Kamath T, Brammer M, Hurvitz SA, Sullivan SD. PMID: 24926422; PMCID: PMC4047276.
      View in: PubMed   Mentions: 13  
    132. Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer. Springerplus. 2014; 3:244. Hurvitz SA, Bosserman LD, Chan D, Hagenstad CT, Kass FC, Smith FP, Rodriguez GI, Childs BH, Slamon DJ. PMID: 24860718; PMCID: PMC4031367.
      View in: PubMed   Mentions: 1  
    133. The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. BMC Cancer. 2014 May 02; 14:307. Tripathy D, Rugo HS, Kaufman PA, Swain S, O'Shaughnessy J, Jahanzeb M, Mason G, Beattie M, Yoo B, Lai C, Masaquel A, Hurvitz S. PMID: 24885258; PMCID: PMC4011780.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    134. Treatment of trastuzumab-refractory, HER2-positive metastatic breast cancer. Clin Adv Hematol Oncol. 2014 Apr; 12(4):260-2. Hurvitz S. PMID: 25003356.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    135. nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treat Rev. 2014 Jun; 40(5):614-25. Megerdichian C, Olimpiadi Y, Hurvitz SA. PMID: 24560997.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    136. PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. J Neurooncol. 2014 Mar; 117(1):7-13. Peddi PF, Hurvitz SA. PMID: 24469856; PMCID: PMC3980725.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    137. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer. 2014 Mar 01; 120(5):642-51. Welslau M, Di?ras V, Sohn JH, Hurvitz SA, Lalla D, Fang L, Althaus B, Guardino E, Miles D. PMID: 24222194.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    138. Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer. Breast Cancer Res Treat. 2013 Dec; 142(3):603-9. Hurvitz SA, Lalla D, Crosby RD, Mathias SD. PMID: 24218050; PMCID: PMC3855533.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    139. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat. 2013 Oct; 141(3):437-46. Hurvitz SA, Dalenc F, Campone M, O'Regan RM, Tjan-Heijnen VC, Gligorov J, Llombart A, Jhangiani H, Mirshahidi HR, Tan-Chiu E, Miao S, El-Hashimy M, Lincy J, Taran T, Soria JC, Sahmoud T, Andr? F. PMID: 24101324; PMCID: PMC3824346.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    140. Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. Cancer Treat Rev. 2014 Mar; 40(2):320-6. Peddi PF, Shatsky RA, Hurvitz SA. PMID: 24011786.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    141. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013 Jul 01; 19(13):3693-702. Andr? F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J. PMID: 23658459.
      View in: PubMed   Mentions: 120     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    142. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol. 2013 Mar; 9(3):319-26. Peddi PF, Hurvitz SA. PMID: 23469968; PMCID: PMC3860880.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    143. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013 Mar 20; 31(9):1157-63. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA. PMID: 23382472.
      View in: PubMed   Mentions: 147     Fields:    Translation:HumansCTClinical Trials
    144. The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies. Ther Adv Med Oncol. 2012 Sep; 4(5):235-45. Hurvitz SA, Kakkar R. PMID: 22942906; PMCID: PMC3424498.
      View in: PubMed   Mentions: 11  
    145. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma. J Immunother. 2012 Sep; 35(7):534-43. Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, van Rooijen N, Timmerman JM. PMID: 22892450.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    146. Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev. 2013 May; 39(3):219-29. Hurvitz SA, Hu Y, O'Brien N, Finn RS. PMID: 22658319; PMCID: PMC3835685.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimals
    147. Analysis of Fc? receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 2012 Jun 15; 18(12):3478-86. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM. PMID: 22504044; PMCID: PMC3821872.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    148. Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2012 Apr 03; 4:35-51. Hurvitz SA, Kakkar R. PMID: 24367193; PMCID: PMC3846547.
      View in: PubMed   Mentions: 7  
    149. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10; 29(32):4286-93. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. PMID: 21990397.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansCTClinical Trials
    150. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 2011 Apr; 12(4):369-76. Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagiello-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroose R, Hurvitz S, Ba?os A, Adewoye H, Hei YJ, Lindsay MA, Rupin M, Cabaribere D, Lemmerick Y, Mackey JR, TRIO 010 investigators. PMID: 21429799.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    151. Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint. Cancer Treat Rev. 2011 Nov; 37(7):495-504. Hurvitz SA. PMID: 21315516; PMCID: PMC3821870.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    152. Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol. 2011 Feb; 23(1):37-43. Callahan R, Hurvitz S. PMID: 21500375; PMCID: PMC4307801.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    153. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010 Dec 01; 28(34):5110-5. Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA. PMID: 20975068.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    154. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Clin Breast Cancer. 2010 Aug 01; 10(4):307-12. Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F. PMID: 20705564.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    155. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009 Oct 15; 15(20):6446-53. Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, Erlichman C, Lowy I, Timmerman JM. PMID: 19808874; PMCID: PMC2763019.
      View in: PubMed   Mentions: 136     Fields:    Translation:HumansCTClinical Trials
    156. Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists. Oncologist. 2009 Sep; 14(9):883-90. Hurria A, Wong FL, Pal S, Chung CT, Bhatia S, Mortimer J, Somlo G, Hurvitz S, Villaluna D, Naeim A. PMID: 19726455.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    157. What's positive about 'triple-negative' breast cancer? Future Oncol. 2009 Sep; 5(7):1015-25. Hurvitz SA, Finn RS. PMID: 19792970.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    158. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 2008 Nov 01; 113(9):2385-97. Hurvitz SA, Pietras RJ. PMID: 18819158.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    159. Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers. J Clin Oncol. 2008 Nov 20; 26(33):5386-92. Hurria A, Wong FL, Villaluna D, Bhatia S, Chung CT, Mortimer J, Hurvitz S, Naeim A. PMID: 18955446; PMCID: PMC2651077.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    160. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J Immunol. 2008 Sep 15; 181(6):4131-40. Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM. PMID: 18768870.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    161. Primary dural marginal zone lymphoma in a woman with inflammatory breast cancer. J Clin Oncol. 2008 Jan 10; 26(2):326-8. Ancheta RG, Lewin H, Said J, Hurvitz SA. PMID: 18182673.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    162. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr Opin Oncol. 2005 Sep; 17(5):432-40. Hurvitz SA, Timmerman JM. PMID: 16093791.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    163. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol Ther. 2005 Jun; 5(6):841-52. Hurvitz SA, Timmerman JM. PMID: 15952914.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    Sara's Networks
    Concepts (425)
    Derived automatically from this person's publications.
    Co-Authors (76)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department